5 reports

  • Vermillion Enters into Partnership Agreement with Southern California Permanente
  • Mar 29, 2017: Vermillion Reports Fourth Quarter and Full Year 2016 Results

The company intends to use the proceeds to increase test sales and improve reimbursement for OVA##, expand the commercial opportunity into new markets and advance one or more next-generation ovarian cancer diagnostic tests.

  • Healthcare
  • Pharmaceutical
  • United States
  • Company
  • Ciphergen Biosystems, Inc.
  • Vermillion Completes Private Placement Of Shares US$18 Million Upon Exercise Of Warrants
  • Mar 29, 2017: Vermillion Reports Fourth Quarter and Full Year 2016 Results

The company intends to use the proceeds to increase test sales and improve reimbursement for OVA##, expand the commercial opportunity into new markets and advance one or more next-generation ovarian cancer diagnostic tests.

  • United States
  • Company
  • Ciphergen Biosystems, Inc.

Liabilities & Shareholders' Equity Total Liabilities & Shareholders' Equity ## ## ## ## ## Tangible Other Assets Intangible Other Assets ## ## ## ## ## ## ## ## ## ## Total Assets ## ## ## ## ## Total Current Liabilities Accounts Payable ## ## ## ## ## ## ## ## ##

  • United States
  • Company Financials
  • Ciphergen Biosystems, Inc.
  • OF CONTENTS
  • MERGERS AND ACQUISITIONS - DEAL REPORTS

Correlogic' s research areas include: ##) OvaCheck& reg; blood test for detection of ovarian cancer; ##) MammoCheck& reg;, a blood test for detection of breast cancer; ##) ProstaCheck& reg; is a blood test for prostate cancer etc.

  • United States
  • Corporate Finance
  • Ciphergen Biosystems, Inc.

Companies ##.

  • United States
  • Company Financials
  • Ciphergen Biosystems, Inc.